Frequency and Prognostic Significance of Intertumoural Heterogeneity in Multifocal Jejunoileal Neuroendocrine Tumours

Simple Summary Well differentiated jejunoileal neuroendocrine tumors (SI-NETs) commonly present as multiple primaries, which are believed to be clonally unrelated. Our study aimed to explore whether these multifocal lesions show intertumoral differences between the most common histomorphological parameters and if so, whether these differences can be associated with patient prognosis. While WHO grade and standard neuroendocrine markers were found to be mostly stable, we observed intertumoral heterogeneity in the expression of SSTR2, CDX2, and serotonin, but observed no survival differences between the expression groups or in comparison to unifocal NETs. Although multifocal SI-NETs showed some degree of heterogeneity in their central morphological parameters, these findings do not appear to be of major clinical significance, rendering an extensive testing of all multifocal lesions as not necessarily required. Abstract Background: A recent study found that multifocal jejunoileal neuroendocrine tumors (SI-NETs) are genetically unrelated synchronous neoplasms. So far, it is unclear if this finding of synchronous independent neoplasms is mirrored by heterogeneity of key morphological parameters of SI-NETs and how it affects patient survival. Methods: We separately assessed WHO grade (based on the Ki-67 index), expression of basal diagnostic markers (synaptophysin/chromogranin A/CDX2/serotonin), SSTR2a, and the contexture of the immunogenic microenvironment in 146 separate tumors from 28 patients with multifocal SI-NETs and correlated the results with clinicopathological factors and survival. Results: Synaptophysin and chromogranin A were strongly expressed in all tumors. WHO grade was concordant within all multifocal lesions in more than 80% of cases and the highest grade was usually found in the most advanced primary. Intertumoral expression of serotonin, SSTR2, and CDX2 was discrepant in 32%, 43%, and 50% of all patients, respectively. Neither heterogeneity of any of the aforementioned markers nor multifocality itself had any impact on patient survival (p = n.s.). Discussion: Multifocal SI-NET show considerable variability in some of the central diagnostic parameters. However, neither intertumoral heterogeneity of those parameters nor multifocality itself had any impact on patient survival, showing that extensive testing of all multifocal lesions is not necessarily required.

[1]  B. Goichot,et al.  18F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors , 2022, The Journal of Nuclear Medicine.

[2]  M. Luster,et al.  Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms , 2021, Journal of neuroendocrinology.

[3]  M. Kendrick,et al.  Multifocality is not associated with worse survival in sporadic pancreatic neuroendocrine tumors , 2021, Journal of surgical oncology.

[4]  J. Garber,et al.  Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs) , 2021, JCO precision oncology.

[5]  D. Bartsch,et al.  Prognostic Factors in Curative Resected Locoregional Small Intestine Neuroendocrine Neoplasms , 2021, World Journal of Surgery.

[6]  E. Larsson,et al.  Independent somatic evolution underlies clustered neuroendocrine tumors in the human small intestine , 2020, Nature Communications.

[7]  A. Bellizzi Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can Brown do for you? , 2019, Human pathology.

[8]  He Xiao,et al.  Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors. , 2019, Pathology, research and practice.

[9]  J. Cates,et al.  Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours? , 2018, Histopathology.

[10]  H. Schildhaus,et al.  Der prädiktive Wert der PD-L1-Diagnostik , 2018, Der Pathologe.

[11]  W. Ito,et al.  High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. , 2018, Human pathology.

[12]  A. Gangi,et al.  Multifocality in Small Bowel Neuroendocrine Tumors , 2018, Journal of Gastrointestinal Surgery.

[13]  T. O'Dorisio,et al.  Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors? , 2017, Pancreas.

[14]  E. Ingelsson,et al.  A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors , 2017, Endocrine-related cancer.

[15]  I. Endo,et al.  Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors , 2017, Digestion.

[16]  A. Bellizzi,et al.  Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival , 2017, Annals of Surgical Oncology.

[17]  J. Berlin,et al.  Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.

[18]  E. Krenning,et al.  ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum , 2016, Neuroendocrinology.

[19]  Michael Goodman,et al.  Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies , 2015, Modern Pathology.

[20]  Richard A Armstrong,et al.  When to use the Bonferroni correction , 2014, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[21]  S. Baldus,et al.  Neuroendokrine Neoplasien des distalen Jejunums und Ileums , 2014, Der Pathologe.

[22]  T. Gress,et al.  ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas , 2011, Neuroendocrinology.

[23]  E. Baudin,et al.  ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.

[24]  B. Wiedenmann,et al.  Neuroendocrine tumors of midgut and hindgut origin: Tumor‐node‐metastasis classification determines clinical outcome , 2011, Cancer.

[25]  D. Shutt,et al.  Tomography Imaging Targets in Ileal and Pancreatic Neuroendocrine Tumors , 2010 .

[26]  A. Scarpa,et al.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.

[27]  L. Sobin,et al.  Carcinoids of the jejunum and ileum , 1997, Cancer.

[28]  P. Neuhaus,et al.  Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. , 1996, Gut.

[29]  M. Schwaiger,et al.  Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.